Abstract
Positron emission tomography (PET) or PET/CT with 2-[fluorine 18] fluoro-2-deoxy-d-glucose (FDG) plays an important role for diagnosis and management in patients with various malignancies, as the recent meta-analysis has shown significant changes of management in approximately one-third patients with various malignancies with additional use of FDG PET scan. In gynecological region, the National Comprehensive Cancer Network Overian/Uterine Cancer Guideline recommends the use of FDG PET in detecting recurrent lesions with negative CT/MR imaging findings and rising tumor marker levels and in obtaining confirmative diagnosis of CT/MR-indeterminate lesions. In urogenital region, the evidences indicating of the utility of FDG PET for initial staging and re-staging after surgery are now being accumulated, regardless of some inherent limitations in evaluation primary lesions. At this final chapter for the review of the feasibility of FDG PET/CT in abdomino-pelvic regions, the content is focused on the utility and limitations of this technique in gynecological/urogenital oncology.
